Exclusive

Publication

Byline

Location

State of Tennessee Department Of Revenue Issues Solicitation Notice for Unclaimed Vehicle Portal

Nashville, Tenn., Sept. 3 -- The State of Tennessee Department Of Revenue (34717-01017) for Unclaimed Vehicle Portal. Description: The State is looking for a single, experienced vendor to implement ... Read More


Telangana Govt marks 1,000 days, highlights welfare and development initiatives

Hyderabad, Aug. 31 -- The Telangana government led by Chief Minister A. Revanth Reddy will complete 1,000 days in office on September 1, highlighting a series of welfare, development and administrativ... Read More


HDFC bank share : సీఈఓ రాజీనామా చేసినా.. లాభాల్లో హెచ్‌డీఎఫ్‌సీ బ్యాంక్ షేర్లు! ఇప్పుడు కొనొచ్చా?

భారతదేశం, ఆగస్టు 31 -- భారత బ్యాంకింగ్ రంగానికి దిశానిర్దేశం చేసే ప్రైవేట్ దిగ్గజం హెచ్‌డీఎఫ్‌సీ బ్యాంక్ మేనేజింగ్ డైరెక్టర్, సీఈఓ శశిధర్ జగదీశన్ తన పదవికి రాజీనామా చేయనున్నట్లు ప్రకటించడం దలాల్ స్ట్ర... Read More


US-Iran War: PM Modi to meet Iranian President Pezeshkian during SCO summit, report says

New Delhi, Aug. 31 -- Prime Minister Narendra Modi is scheduled to meet Iranian President Masoud Pezeshkian during his two-day visit to Kyrgyzstan for the Shanghai Cooperation Organisation (SCO) summi... Read More


Singapore Clinical Trial: FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer

Singapore, Aug. 31 -- The Health Sciences Authority received information related to the study titled 'FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy o... Read More


Singapore Clinical Trial: A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum- Sensitive Ovarian Cancer (PSOC)

Singapore, Aug. 31 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Ver... Read More


Singapore Clinical Trial: An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)

Singapore, Aug. 31 -- The Health Sciences Authority received information related to the study titled 'An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembr... Read More


Singapore Clinical Trial: A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer

Singapore, Aug. 31 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Pl... Read More


Singapore Clinical Trial: ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy.

Singapore, Aug. 31 -- The Health Sciences Authority received information related to the study titled 'ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Com... Read More


Singapore Clinical Trial: A Phase 2, Randomized, Open-Label Study of VVD-133214 in Combination with Pembrolizumab compared with Pembrolizumab monotherapy in participants with advanced colorectal adenocarcinoma (CRC) harboring microsatellite instability (MSI) and/or deficient mismatch repair (DMMR)

Singapore, Aug. 31 -- The Health Sciences Authority received information related to the study titled 'A Phase 2, Randomized, Open-Label Study of VVD-133214 in Combination with Pembrolizumab compared w... Read More